- McKesson’s third-quarter adjusted earnings per share (EPS) was $8.03, exceeding the previous year’s $7.74 and surpassing estimates of $8.01.
- Total revenue reached $95.29 billion, up 18% from the previous year, but slightly below the estimate of $95.86 billion.
- US pharmaceutical revenue grew by 19% year-over-year to $87.11 billion, though it was below the expected $87.94 billion.
- International revenue increased by 6.1% year-over-year to $3.86 billion, slightly surpassing the estimate of $3.82 billion.
- Medical-surgical solutions revenue fell by 2.7% to $2.95 billion, not meeting the projected $3.1 billion.
- Prescription technology solutions revenue rose by 14% year-over-year to $1.37 billion, slightly above the estimate of $1.36 billion.
- Analysts’ ratings include 14 “buy,” 2 “hold,” and 1 “sell” for McKesson’s stock.
Mckesson Corp on Smartkarma
On Smartkarma, an independent investment research network, Baptista Research has recently provided insightful analyst coverage on McKesson Corporation. In one report titled “McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? – Major Drivers,” Baptista Research highlights McKesson’s robust financial performance in the second quarter of fiscal 2025. With record revenues of $93.7 billion and a significant 21% year-over-year increase driven by the U.S. Pharmaceutical segment, McKesson’s strategic partnerships and specialty product distribution have propelled its growth.
In another report by Baptista Research titled “McKesson Corporation: Expanding Oncology & Specialty Pharmaceutical Services As Well As Distribution & Sourcing! – Major Drivers,” McKesson’s first quarter fiscal 2025 earnings are discussed. The company exhibited a 6% revenue increase year-over-year, reaching $79.3 billion, and an 8% rise in adjusted earnings per share to $7.88. These positive results not only exceeded expectations but also led to an upward revision of full-year adjusted earnings per share guidance. Baptista Research‘s analysis showcases McKesson’s continued growth and strategic advancements across its diversified healthcare services.
A look at Mckesson Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
McKesson Corp, a distributor of pharmaceuticals and healthcare products in North America, seems to have a promising long-term outlook based on its Smartkarma Smart Scores. With a strong emphasis on Growth, Resilience, and Momentum scoring high marks, the company demonstrates a positive trajectory in key areas. The Growth score indicates potential for expansion and development, while Resilience and Momentum scores suggest stability and positive market performance. Although the Value score is lower, the company’s focus on innovation and market presence bodes well for its future prospects.
McKesson Corp also receives a moderate score in Dividend, reflecting its ability to provide returns to shareholders. Overall, the company’s profile emphasizes growth, resilience, and momentum, positioning it favorably for long-term success in the healthcare distribution industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
